Lipoplex gene transfer of inducible nitric oxide synthase inhibits the reactive intimal hyperplasia after expanded polytetrafluoroethylene bypass grafting  by Pfeiffer, Tomas et al.
Lipoplex gene transfer of inducible nitric oxide
synthase inhibits the reactive intimal hyperplasia
after expanded polytetrafluoroethylene
bypass grafting
Tomas Pfeiffer, MD, PhD,a Martina Wallich, PhD,b Wilhelm Sandmann, MD,a
Jürgen Schrader, MD, PhD,b and Axel Gödecke, MD, PhDb Düsseldorf, Germany
Objective: Intimal hyperplasia (IH) is most commonly the cause of graft occlusion in infrainguinal bypass grafting for
arterial occlusive disease. We investigated the influence of nitric oxide on the IH of the arterial vessel wall at the region
of prosthetic bypass anastomoses.
Methods: Experiments were performed in 10 Foxhound dogs. We used a technique of inducible nitric oxide synthase
(iNOS) overexpression by a non–virus-mediated, liposome-based iNOS gene transfer. The plasmid pSCMV-iNOS, which
drives the expression of iNOS under control of the cytomegalovirus promoter, was complexed with cationic liposomes
(lipoplexes). Segments of both carotid arteries were pretreated by intramural injection of a lipoplex solution by using an
infiltrator balloon catheter (Infiltrator Drug Delivery Balloon System). In each dog, iNOS was administered at one side,
and a control vector (pSCMV2) was administered at the contralateral side. Carotid arteries were ligated, and bypass grafts
(expanded polytetrafluoroethylene, 6-mm, ring enforced) were implanted on both sides. The proximal and distal
anastomoses (end-to-side fashion; running nonabsorbable sutures) were placed in the pretreated regions. After 6 months,
the prostheses were excised, and the intimal thicknesses of 50 cross sections (orcein staining) of each anastomosis were
measured planimetrically.
Results:The average reduction of the neointima thickness of the iNOS side in proximal anastomoses at the prosthetic wall,
suture region, and arterial wall was 43%, 52%, and 81%, respectively. In distal anastomoses, the average reduction was
40%, 47%, and 52%, respectively. All differences of neointima thickness between the iNOS and control sides were
statistically significant (Wilcoxon test; P < .05).
Conclusions: Inducible NOS expression is an efficient approach for inhibition of IH. In contrast to earlier studies, which
investigated the efficacy of gene therapeutic NOS expression at 3 to 4 weeks after intervention, the novelty of our findings
is that a single local lipoplex-mediated transfection of the vascular wall with iNOS-expressing plasmids leads to a
reduction of IH in a prosthetic in vivo model even after 6 months. Because all components can be manufactured under
Good Manufacturing Practice conditions (the quality-management system of the European pharmaceutical industry
based on ISO 9000), this approach is also amenable to human therapy. (J Vasc Surg 2006;43:1021-7.)
Clinical Relevance: Intimal hyperplasia is a uniform adverse effect after vascular suture, endarterectomy, angioplasty, and
stenting and is the most limiting factor with regard to long-term patency. Eradication of intimal hyperplasia by lipoplex
gene transfer of inducible nitric oxide synthase would be a milestone in the development of vascular and endovascular
procedures. The results of bypass grafting, as well as those of endarterectomies, patch plasties, angioplasties, and stents
in supra-aortic, coronary, visceral, renal, and peripheral vessels, could thus be markedly improved. The manufacturing
process of inducible nitric oxide synthase lipoplexes under Good Manufacturing Practice conditions is well established,
but the substance is commercially not available yet. The promising results presented here should encourage the industry
to commercialize inducible nitric oxide synthase lipoplexes and to foster necessary clinical and experimental studies within
a wide range of possible applications.From the Departments of Vascular Surgery and Kidney Transplantationa
and Physiology,b University Hospital Medical School, Heinrich-
Heine-University Düsseldorf.
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doi:10.1016/j.jvs.2006.01.014Intimal hyperplasia (IH) is most commonly the cause
of graft occlusion in infrainguinal bypass surgery for
arterial occlusive disease. In contrast to prosthetic graft
material, autologous vein grafts have superior biological
properties. Their endothelial surface provides minimal
thrombogenicity; their compliance is similar to that of
arteries. Because venous grafts induce less IH of the anasto-
motic regions than prosthetic grafts, autologous vein grafting
is the gold standard of femoropopliteal and femorodistal re-
vascularization.
Every arterial lesion after vascular surgical procedures
causes a uniform reaction to injury from the vessel wall,
thus leading to IH, which is a main reason for graft fail-
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nous6,7 or prosthetic8-15 bypass grafting has been used.
Mechanisms and causes of IH have not been sufficiently
determined. Nevertheless, the hemodynamics of the bypass
anastomosis significantly influence the development of
IH.16-18 Nitric oxide (NO) is an important endogenously
synthesized modulator of vascular homeostasis. Besides
blood pressure regulation, NO released by vascular endo-
thelial cells exerts many protective functions in arteries,
including inhibition of both thrombosis and invasion of
inflammatory cells. It is important to note that NO inhib-
its the proliferation of vascular smooth muscle cells
(VSMC), thus enabling a gene therapeutic approach for
the local inhibition of neointima formation. Recently, a
safe catheter-based transfection protocol of arterial walls in
vivo that used inducible NO synthase (iNOS)-expressing
plasmids complexed with liposomes was developed. Using
a specific catheter designed to inject drugs directly into the
vascular wall, Muhs et al19 significantly reduced neointima
formation after balloon angioplasty and the in-stent steno-
sis by local overexpression of iNOS. On the basis of this
transfectionmethod, we developed a gene transfer protocol
for the local transfection of the vascular wall-graft anasto-
moses and investigated the long-term therapeutic effect of
a single liposome-mediated gene transfer of iNOS on the
formation of IH.
MATERIALS AND METHODS
Inducible NOS lipoplexes. For the transfection of ca-
rotid arteries, we used the plasmid pSCMV-iNOS, which
drives the expression of the murine iNOS complementary
DNA under the control of the cytomegalovirus promoter. 20
As a control, the iNOS-less vector pSCMV2 was used. For
a transfection plasmid, DNA was complexed with cationic
liposomes (DAC-30; Eurogentec, Seraing, Belgium) ac-
cording to published procedures.19 The lipoplex solution
for catheter administration contained 10 g/mLDNA and
20 g/mL cationic liposomes in a solution of 25 mmol/L
NaCl and 250 mmol/L sucrose.
Experimental procedure. All experiments were per-
formed by authority according to the German law for animal
protection. In Foxhound dogs weighing 30 to 40 kg, the
carotid artery was prepared bilaterally. Anesthesia was in-
duced by Azepromazin (Biokema SA, Crissier, Switzer-
land) and Thiopental (Altana Pharma, Konstanz, Ger-
many) intravenously. After tracheal intubation, inhaled
anesthesia was maintained by nitrous oxide and halothane.
A standardized segment of 12 cm of the carotid artery was
clamped proximally and distally. Through a semicircular
incision in themiddle of the clamped segment, an infiltrator
balloon catheter (Infiltrator; InterVentional Technologies
Europe Ltd, Lisnenan, Letterkenny, Co Donegal, Ireland)
was inserted. The infiltrator catheter had three lumina and
an inflatable balloon with a length of 15mm and a diameter
of 4 mm. The balloon was provided with three longitudinal
bars carrying seven microinjection ports each (Fig 1). After
inflation of the balloon with a standardized pressure ofthree bars, the lipoplex solution was administered through
the microinjection ports into the arterial vessel wall. The
transfection of the arterial vessel wall was performed on a
length of 45 mm by three successive injections of each
400-L lipoplex solution at the proximal and distal side of
the carotid segment. Because the carotid artery was pre-
pared free from connective tissue, the physiologic tissue
resistance was lacking. Therefore, a latex foil with a stan-
dardized tension of 5 N was wrapped around the artery in
the region of the inflated balloon to ensure a consistent
penetration of the microinjection ports into the vessel wall.
In preliminary tests, the concentration of the lipoplex
solution and the tension of the latex membrane had been
optimized with regard to a maximum transfection rate. In
all experiments, the transfection of the vessel wall by lipo-
plex solution was performed in both carotid arteries by
using the iNOSDNAon one side and pSCMV2 as a control
vector on the contralateral side.
Pilot experiments (n  4). To analyze the effect of
iNOS expression on cell proliferation, immunohistochem-
ical pilot studies in four dogs were performed. Segments of
the carotid arteries were transfected by means of the
infiltrator catheter in the technique mentioned previ-
ously with lipoplex solution of iNOS DNA on one side
and pSCMV2 as a control vector on the contralateral side
without graft implantation. The vessels were excised 3
days after transfection.
Cryosections from the transfected vessel sections were
stained with Ki-67 antibodies (Dako, Hamburg, Ger-
many).21 The Ki-67 protein is present during all active
phases of the cell cycle but is absent from resting cells. The
sections were fixed with 4% paraformaldehyde for 10 min-
utes and washed in Tris-buffered saline (5 minutes) treated
with 3% hydrogen peroxide (5 minutes) to block the en-
Fig 1. Infiltrator catheter for intramural administration of lipo-
plex solution into the arterial vessel wall. The balloon, with a
diameter of 4 mm, provides three bars (length, 15 mm) in an angle
of 120° with seven microinjection ports each.dogenous peroxidase activity and then were washed with
JOURNAL OF VASCULAR SURGERY
Volume 43, Number 5 Pfeiffer et al 1023Tris-buffered saline for 5 minutes. Sections were incubated
overnight with the primary antibody against Ki-67 (Fa.
Dako; diluted 1:100). Immunohistochemical detection
was performed with the use of a labeled streptavidin-biotin
method (LSAB kit; Dako). Then the biotinylated link
antibody and peroxidase-labeled streptavidin-horseradish
peroxidase were used for 10 minutes. Finally the sections
were developed with diaminobenzidine. For the evaluation
of total vs Ki-67–positive cells, sections were stained with
hematoxylin of Mayer.22 Nuclei labeled positively for Ki-67
were defined by visual determination in five or more ran-
domly selected fields per cross section of five different areas
of the arterial vessel at 200 magnification. The results
were expressed as the mean percentage of labeled nuclei.
To analyze the transfection efficiency, the cryosections
were stained with monoclonal antibodies against iNOS
protein. Three days after transfection with pSCMV-iNOS
and control plasmid, the arteries were washed with lactated
Ringer solution and frozen in liquid nitrogen. The vessels
were cut in cryosections (10 m) and fixed in 4% parafor-
maldehyde for 10 minutes. After inactivation of endoge-
nous peroxidase (3% hydrogen peroxide for 20-30 min-
utes), sections were incubated with 10% normal horse
serum in Tris-buffered saline for 30 to 45 minutes, fol-
lowed by monoclonal antibodies against iNOS protein (2.5
g/mL; Transduction Laboratories, BD Biosciences, San
Jose, CA, USA) overnight at 4°C. Antibody binding was
detected with biotinylated anti-mouse immunoglobulin G
(Vector, Laboratories, Burlingame, CA, USA) for 3 hours
and in a solution of peroxidase-linked avidin-biotin perox-
idase complex (ABC kit; Vector Laboratories, Burlingame,
CA, USA) for another 1.5 hours. Slices were developed by
the nickel-enhanced diaminobenzidine procedure.
Long-term experiments (n  10). To address the
question to which extent iNOS expression modulates neo-
intima formation after polytetrafluoroethylene graft im-
plantation, long-term experiments were performed in 10
dogs. After the above-mentioned steps in each carotid
artery, a longitudinal incision with a standardized length of
15 mm was placed in the middle of the proximal and distal
transfected area. On both sides an expanded polytetrafluo-
roethylene prosthesis with a standardized length of 10 cm
(IMPRA expanded polytetrafluoroethylene Thinwall Vas-
cular Graft Carboflo Flex TW SM Bead Carbon; 6-mm
diameter; ring enforced; Bard, Murray Hill, New Jersey,
USA) was anastomosed as a bypass graft proximally and
distally in an end-to-side manner by using nonabsorbable
running sutures (6-0 Gore-Tex; W. L. Gore & Associates,
Inc, Flagstaff, Ariz). After a double ligation of each carotid
artery between the anastomoses, the clamps were removed,
and the polytetrafluoroethylene bypass grafts were per-
fused. Wounds were closed with absorbable sutures. Nei-
ther heparin nor antiplatelet medications were adminis-
tered. The same vascular surgeon performed all surgical
procedures of 10 experiments.
All prostheses were explanted after 6 months. Before
explantation, angiography of the aortic arch and the carotid
arteries was performed. Through a proximal incision, thecarotid arteries and the prostheses were perfused with
Ringer solution followed by 4% formalin. Subsequently the
lumina were filled with liquid gelatin to maintain the form
and diameter of the vessel walls. After solidifying of the
gelatin, the prostheses and the adjacent arteries were re-
moved and fixed in 4% formalin.
Fifty histologic cross sections of each anastomosis, each
at a distance of 300m,were taken and stained with orcein.
In each cross section, the average thickness of the neoin-
tima at the prosthesis wall and at the arterial wall and the
maximum thickness of the neointima at the suture region
were assessed by planimetry (anOlympus PX60microscope
(Olympus Deutschland GmbH, Hamburg, Germany) and
a computer equipped with image-analysis software; SiS
GmbH,Münster, Germany). The planimetry of all sections
was performed blinded by two independent investigators.
The measured values of both were averaged. The data were
analyzed by using the Wilcoxon test and SPSS 10.1 (SPSS
Inc, Chicago, Ill).
RESULTS
In pilot studies, we investigated to what extent catheter-
mediated lipoplex gene transfer into the canine arterial
vessel wall allowed expression of iNOS with the formation
of bioactive NO. Fig 2 shows the immunohistochemical
staining of vessel segments transfected with 4 g of
pSCMV-iNOS (left) and pSCMV2 (right), respectively.
The transfection with pSCMV-iNOS led to iNOS expres-
sion throughout the vascular wall, whereas the control
vector–transfected segments showed only a faint back-
ground staining of elastic fibers. Because NO is known to
inhibit smooth muscle cell proliferation, we investigated to
what extent cells undergoing mitosis were found 3 days
after transfection. As shown in Fig 3, abundant Ki-67–
positive cells were detected in pSCMV2-transfected arterial
segments. In contrast, iNOS-expressing vessels showed
much lower levels of cell proliferation that were similar to
the levels found in an untreated vessel.
In all chronic experiments, the prostheses healed with-
out infection. After all prostheses were harvested, 6 months
after implantation, there was no difference in healing char-
acteristics between the right and left side treated with iNOS
and the control vector. The intra-arterial angiographies,
which were performed before explantation, showed patent
prostheses in all cases, without any stenoses. The minimum
diameters of the proximal and distal anastomoses measured
angiographically showed no significant differences between
the iNOS (3.8  0.2 mm and 3.8  0.4 mm, respectively)
and the control side (3.8  0.29 mm and 3.6  0.30 mm,
respectively; mean SD). The orcein-stained cross sections
of all anastomoses presented with a neointima formation at
the arterial vessel wall, the prosthetic wall, and the suture
region. Neither graft thromboses nor thinning of the arte-
rial wall were observed. The average thickness of the neo-
intima differed between arterial vessel wall, prosthetic wall,
and suture region with different patterns of proximal anas-
tomoses and distal anastomoses. In proximal anastomoses,
the maximum thickness of the neointima was measured at
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imum thickness of the neointima was found at the arterial
wall. This pattern was identical in the iNOS and the control
side. However, in anastomoses transfected with iNOS, the
thickness of the neointima was significantly reduced. The
intima thickness of proximal anastomoses at the prosthetic
wall, suture region, and arterial wall was 108.7  61.0 m
vs 191.7 66.2 m, 46.3 25.4 m vs 95.7 31.7 m,
and 10.0 14.4 m vs 52.9 41.3 m, respectively. The
corresponding intimal thickness of distal anastomoses was
100.3  75.2 m vs 166.7  61.9 m, 89.8  41 m vs
168.8  55.1 m, and 146.7  121.8 m vs 307.7 
161.8 m, respectively (mean  SD). The average reduc-
tion of intimal thickness of the iNOS side in proximal
anastomoses at the prosthetic wall, suture region, and
arterial wall was 43%, 52%, and 81%, respectively; in distal
anastomoses, the average reduction was 40%, 47%, and
52%, respectively. All differences of intimal thickness be-
tween the iNOS and the control side were statistically signifi-
cant (Wilcoxon test; P  .05; Fig 4). In most cross sections,
the distribution of IH was nonuniform. Typically the IH
occurred on only one side of the anastomosis, whereas the
other side showed a thin intima formation (Fig 5).
DISCUSSION
The gene therapy approach used for the long-term
inhibition of IH in response to prosthetic graft implanta-
tion was very efficient in this study. The method is based on
the expression of iNOS as a therapeutic gene and the use of
a nonviral lipoplex-mediated transfection in combination
with the infiltrator catheter as an efficient device for local
gene delivery. We could show that a single transfection at
the time of graft surgery was effective to substantially
reduce IH even after 6 months.
An efficient therapy to inhibit restenosis after pros-
thetic graft implantation is an unsolved problem and poses
a major challenge of clinical research. In general, IH is
the result of an increased proliferation and migration of
Fig 2. Immunohistochemical detection of inducible n
sections 3 days after pSCMV-iNOS and pSCMV2 (con
expression vessel segments (left).VSMCs, which can reach substantial thickness in athero-sclerotically altered vessels in response to surgical trauma.
Because only a limited arterial segment is affected, a local
therapeutic approach seems to be a promising option to
inhibit IH. Because the target vessels are easily accessible
during surgery, a local pharmacologic intervention during
the operation could be easily performed. However, because
drugs applied to the vessel wall would be washed out
rapidly, no benefit of a single-dose treatment can be ex-
pected because the induction of smooth muscle cell prolif-
eration is a slow-developing process. A gene therapeutic
approach with the aim to produce sustained levels of inhib-
itory factors at the site of operation could be suitable to
solve the problem.
Local vascular gene therapy approaches have been de-
veloped, mainly in the field of interventional cardiology,
with the aim to inhibit restenosis after balloon angioplasty.
Among the “therapeutic genes” expressed at the site of
injury, NO synthases have repeatedly been shown to atten-
uate restenosis in several experimental models.23-25
NO has been shown to inhibit VSMC proliferation
in vitro and in vivo.26 It has well been established that in
smooth muscle cells, NO interferes with the cell cycle at the
G0/G1 restriction point by upregulation of the cell-cycle
inhibitors p21 and p27, thus leading to suppression of the
cdk2–cyclin A, cdk4–cyclin D, and cdk2–cyclin E complex
formation; these are essential for cell-cycle progression. In
addition, a direct phosphorylation of cdk2 and the retino-
blastoma protein in response to NO has also been impli-
cated in NO’s antiproliferative effects.27 In line with this
finding, we have shown here that iNOS expression reduced
the number of cells progressing through the cell cycle,
because the number of Ki-67–positive cells was massively
reduced in iNOS-expressing vessel segments. In conse-
quence, targeting of cell-cycle regulators seems to be a
normal function of NO andmay explain, at least in part, the
antiatherosclerotic properties of endothelium-derived NO.
The lipophilic character of NO and its ability to rapidly
diffuse through cell membranes offers another advantage of
oxide synthase (iNOS) expression in cells of arterial
ector) transfection. Note the intense staining of iNOSitric
trol vthe iNOS gene transfer as a therapeutic approach. Gene
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overexpression of proteinaceous cell-cycle inhibitors such
as p21 require a high transfection rate because the biolog-
ical effects of p21 are restricted to the transfected cells only.
This kind of approach is usually based on viral transfection
systems that allow a high transfection rate in vivo. Given
NO’s paracrine mode of action, we anticipated that trans-
fection of only a fraction of the VSMCs would be sufficient
to elicit a therapeutic effect. Indeed, we could demonstrate
that a liposomal gene transfer with plasmid vectors led to
widespread iNOS expression in the vascular wall. Using a
transfection protocol similar to that applied in this study,
Muhs et al28 demonstrated that 44% of VSMCs could be
transfected after lipoplex injection into porcine coronary
Fig 3. Effect of inducible nitric oxide synthase (iNOS) gene transfer
on smooth muscle cell proliferation 3 days after transfection with the
pSCMV-iNOS vector (top left) or the control vector pSCMV2 (top
right). Tissue slices were stained for nuclear Ki-67 accumulation as
an indicator of cell-cycle progression. Ki-67–positive cells are
stained brown (an example is circled); Ki-67–negative nuclei ap-
pear blue. Quantitative results of Ki-67–positive cells in control
vector–transfected (n 4) and pSCMV-iNOS–transfected (n 4)
vessels are shown (bottom). In comparison, the value of an un-
treated vessel is shown.arteries in vivo, and it can be assumed that we reachedsimilar levels. This unexpected high transfection rate is
most likely the result of a local liposome depot that is
formed within the media after the direct injection of the
liposomes, thus leading to a prolonged contact time. It is
important to note that the combination of the specific
drug-delivery catheter, the infiltrator, with liposomal gene
transfer allowed us to avoid the use of a viral transfection
system, which maybe associated with the risk of transfer of
replication-competent viruses.
An important finding of this study is the long-lasting
biological effect of a single iNOS transfection in the context
of prosthetic graft surgery. The detailed morphometric
analysis 6 months after surgery revealed that the iNOS-
mediated reduction of IH averaged out at 50% of the
control-transfected vessels, with the highest inhibition of
81% in the free arterial wall of the proximal anastomosis. A
similar therapeutic effect of NOS gene transfer has been
reported for the modulation of IH after balloon angio-
plasty.29,30 Signs of local cytotoxicity or local inflamma-
tion, such as thinning of the arterial wall or thrombosis as
an adverse effect of NO, were not detected.
The possible stimulus of the gene delivery approach for
IH by balloon injury has to be discussed as a study limita-
tion. The pilot experiments showed abundant Ki-67–
positive cells in pSCMV2-transfected arterial segments.
However, the infiltration technique by means of the infil-
trator catheter was not comparable to a model of balloon
injury by overdilation of the vessel wall, because the inflated
balloon of the infiltrator catheter and the lumen of the
treated arteries had the same diameter. Therefore, we esti-
Fig 4. Polytetrafluoroethylene bypass grafts were inserted into
the carotid artery of both sides in 10 foxhound dogs. The anasto-
motic region was transfected with pSCMV-iNOS lipoplexes on
one side and with lipoplexes of a pSCMV2 control vector on the
contralateral side. After 6 months, the prostheses were excised. In
50 cross sections of each anastomosis, the intimal thickness over
the arterial vessel wall, the suture region, and the prosthetic wall
was measured planimetrically.Means and standard deviations of 10
proximal and 10 distal anastomoses are given. The thickness of the
neointima after inducible nitric oxide synthase (iNOS) transfection
was significantly reduced (Wilcoxon test; P  .05).mated that the caused vessel wall injury was only mild and
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long-term experiments, mainly the anastomoses with the
prosthetic grafts acted as a complex injury. Also, other
authors did not use the infiltrator catheter as a method of
vessel wall injury but added stents as injuring agents in their
coronary in vivo models.19,25
In this study, the canine model was used because the
size of the treated vessels had to correspond to human
arteries. Infiltrator catheters, grafts, and sutures should be
applicable for later human trials. In this model, vascular
injury induces IH, but the extent of this reaction is not
comparable to the human situation, in which atheroscle-
rotic vessels receive an additional proliferative stimulus by
graft surgery. These characteristics may explain why there
was neither a graft occlusion nor an angiographically de-
tectable stenosis, although intimal thickness of the iNOS
and the control vessels was different when analyzed histo-
logically. To achieve a clinically relevant IH in the control
group, presenting with severe stenosis or occlusion would
require a two-hit animal model with preinjured vessels due
to feeding an atherogenic diet and subsequently the im-
plantation of the prosthesis. Such models have been real-
ized in swine to study the effects of balloon angioplasty.31
Although they resemble more closely the human pathol-
ogy, these models require much higher numbers of exper-
imental animals because the degree of cross-sectional oc-
clusion in angiographically detectable stenoses ranged from
50% to 95% in this model. To study the long-term
Fig 5. Typical histologic finding of a bypass anastomo
nitric oxide synthase (iNOS; left) or a control vector (righ
inhibition of intimal hyperplasia after iNOS transfection
anastomoses of the same animal. A, Arterial wall; P
magnification, 10).inhibitory effects of a single local iNOS transfection, werather used a more reproducible model of IH for proof of
principle because long-term efficacy is an important prereq-
uisite for the more slowly developing graft stenoses.
Although we did not analyze the time course of iNOS
expression in this study, it is probable that the plasmid-
mediated iNOS expression occurs only transiently. Fur-
thermore, it remains unclear how the sustained biological
effect may be mediated by a single transfection at the time
of operation. The answer may be found in the kinetics of
neointima formation in response to a vascular injury. It
seems that VSMC proliferation starts approximately 24
hours after the vessel trauma and proceeds on a high level
during the following 14 days. Tanner et al32 demonstrated
that the expression of the cell-cycle inhibitor p21 is sup-
pressed during this period and increases again at day 14
after development of vascular lesion. Similarly, the expres-
sion of p27, another inhibitor of cell-cycle progression,
declines on day 1 after vascular injury and also recovers
around day 14. In contrast, smooth muscle cell prolifera-
tion increases at day 1 and declines to a lower level around
day 14. As pointed out previously, NO induces p21 and
p27 expression. Although we did not analyze the expres-
sion of these cell-cycle regulators in our model, it seems
likely that induction of these proteinsmay have contributed to
reduce the proliferation rate of VSMCs during the early and
highly active phase of IH.
In summary, iNOS expression is an efficient approach
for inhibition of IH and has been successfully used in viral
er transfection of the arterial vessel wall with inducible
ymmetric formation of neointima (N) of the control and
shown, as are corresponding cross sections of proximal
ytetrafluoroethylene prosthesis (stain, orcein; originalsis aft
t). As
are
, poland nonviral gene therapeutic approaches.19,23,25,26,29-31
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of gene therapeutic NOS expression at 3 to 4 weeks after
intervention,33-36 the novelty of our findings is that a single
local lipoplex-mediated transfection of the vascular wall
with iNOS-expressing plasmids leads to a reduction of IH
in a prosthetic in vivo model even after 6 months. Because
all components required for the production of the lipo-
plexes and the catheters can be manufactured under Good
Manufacturing Practice conditions, this approach is also
amenable to human therapy.19,21,32
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